I like the new 3 pillar clinical program structure outlined in the Yearly Report. At least we can see some direction of the trials now and it is pleasing to see a focus on patients with PI3K pathway and VEGFR3 mutations
From the report:
"Since stepping into the CEO role in May, we have completed a full portfolio review. As a result, we are streamlining the paxalisib clinical development program into three pillars; adult brain cancer, paediatric brain cancer and brain metastases. As targeted therapeutics, both paxalisib and EVT801 have the potential to benefit a number of patients with PI3K pathway and VEGFR3 mutations respectively. Many of the recently announced clinical studies will enrol patients with these mutations. etc...........
- Forums
- ASX - By Stock
- KZA
- Ann: 2023 Corporate Governance Statement
Ann: 2023 Corporate Governance Statement, page-7
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online